학술논문
121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2023 20 Supplement
Subject
Language
ISSN
2590-0188